Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 204.55 Billion KRW | 33.99% |
| 2022 | 152.67 Billion KRW | 20.11% |
| 2021 | 127.1 Billion KRW | 131.02% |
| 2020 | 55.01 Billion KRW | 115.81% |
| 2019 | 25.49 Billion KRW | 14.35% |
| 2018 | 22.29 Billion KRW | 31.35% |
| 2017 | 16.97 Billion KRW | -16.17% |
| 2016 | 20.24 Billion KRW | 42.52% |
| 2015 | 14.2 Billion KRW | -32.94% |
| 2014 | 21.18 Billion KRW | 10.83% |
| 2013 | 19.11 Billion KRW | 8.81% |
| 2012 | 17.56 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 79.03 Billion KRW | 3.4% |
| 2024 Q3 | 73.53 Billion KRW | -27.75% |
| 2024 Q1 | 76.43 Billion KRW | 43.36% |
| 2023 Q4 | 53.31 Billion KRW | -4.92% |
| 2023 Q1 | 43.16 Billion KRW | 9.13% |
| 2023 Q3 | 56.07 Billion KRW | 7.84% |
| 2023 FY | 204.55 Billion KRW | 33.99% |
| 2023 Q2 | 52 Billion KRW | 20.48% |
| 2022 Q3 | 37.61 Billion KRW | -6.8% |
| 2022 Q2 | 40.36 Billion KRW | 7.92% |
| 2022 FY | 152.67 Billion KRW | 20.11% |
| 2022 Q1 | 37.39 Billion KRW | 1.84% |
| 2022 Q4 | 39.55 Billion KRW | 5.14% |
| 2021 Q3 | 51.11 Billion KRW | 154.06% |
| 2021 Q2 | 20.12 Billion KRW | 5.05% |
| 2021 Q4 | 36.72 Billion KRW | -28.16% |
| 2021 FY | 127.1 Billion KRW | 131.02% |
| 2021 Q1 | 19.15 Billion KRW | 16.04% |
| 2020 Q2 | 5.24 Billion KRW | -80.96% |
| 2020 Q3 | 55.08 Billion KRW | 949.28% |
| 2020 Q4 | 16.5 Billion KRW | -70.03% |
| 2020 Q1 | 27.57 Billion KRW | 330.6% |
| 2020 FY | 55.01 Billion KRW | 115.81% |
| 2019 Q1 | 5.85 Billion KRW | -17.22% |
| 2019 FY | 25.49 Billion KRW | 14.35% |
| 2019 Q4 | 6.4 Billion KRW | -2.42% |
| 2019 Q2 | 5.54 Billion KRW | -5.26% |
| 2019 Q3 | 6.56 Billion KRW | 18.25% |
| 2018 Q4 | 7.07 Billion KRW | 28.3% |
| 2018 Q2 | 4.03 Billion KRW | -21.85% |
| 2018 Q1 | 5.16 Billion KRW | -29.38% |
| 2018 FY | 22.29 Billion KRW | 31.35% |
| 2018 Q3 | 5.51 Billion KRW | 36.54% |
| 2017 Q1 | 5.36 Billion KRW | -4.63% |
| 2017 FY | 16.97 Billion KRW | -16.17% |
| 2017 Q4 | 7.31 Billion KRW | 54.0% |
| 2017 Q2 | 4.65 Billion KRW | -13.09% |
| 2017 Q3 | 4.75 Billion KRW | 2.02% |
| 2016 FY | 20.24 Billion KRW | 42.52% |
| 2016 Q1 | 4.74 Billion KRW | 3.59% |
| 2016 Q2 | 6.39 Billion KRW | 34.77% |
| 2016 Q4 | 5.62 Billion KRW | -27.03% |
| 2016 Q3 | 7.7 Billion KRW | 20.43% |
| 2015 Q4 | 4.58 Billion KRW | 40.16% |
| 2015 Q2 | 3.22 Billion KRW | -27.74% |
| 2015 Q1 | 4.46 Billion KRW | -6.25% |
| 2015 FY | 14.2 Billion KRW | -32.94% |
| 2015 Q3 | 3.26 Billion KRW | 1.36% |
| 2014 Q3 | 6.79 Billion KRW | 9.37% |
| 2014 Q1 | 3.42 Billion KRW | -39.68% |
| 2014 FY | 21.18 Billion KRW | 10.83% |
| 2014 Q4 | 4.76 Billion KRW | -29.91% |
| 2014 Q2 | 6.21 Billion KRW | 81.3% |
| 2013 Q2 | 3.42 Billion KRW | 20.64% |
| 2013 Q4 | 5.67 Billion KRW | -20.87% |
| 2013 Q3 | 7.17 Billion KRW | 109.6% |
| 2013 Q1 | 2.83 Billion KRW | -38.31% |
| 2013 FY | 19.11 Billion KRW | 8.81% |
| 2012 FY | 17.56 Billion KRW | 0.0% |
| 2012 Q4 | 4.6 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | -85.985% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -2507.236% |
| BINEX Co., Ltd. | 55.67 Billion KRW | -267.412% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -2542.819% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | -213.19% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | -531.942% |
| Helixmith Co., Ltd | 37.36 Billion KRW | -447.429% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 28.461% |
| Medy-Tox Inc. | 110.88 Billion KRW | -84.478% |
| Peptron, Inc. | 16.65 Billion KRW | -1128.099% |
| Amicogen, Inc. | 52.82 Billion KRW | -287.251% |
| Genexine, Inc. | 41.62 Billion KRW | -391.394% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -1165.329% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | -107.423% |
| ALTEOGEN Inc. | 40.93 Billion KRW | -399.713% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | -128.709% |
| SillaJen, Inc. | 5.11 Billion KRW | -3901.357% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -697.056% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -480.317% |
| Genomictree Inc. | 16.26 Billion KRW | -1157.674% |
| MedPacto, Inc. | 26.91 Billion KRW | -659.895% |
| D&D Pharmatech | 32.16 Billion KRW | -536.003% |
| EASY BIO,Inc. | 29.67 Billion KRW | -589.403% |
| GI Innovation, Inc. | 57.59 Billion KRW | -255.181% |